Alkermes plc

Alkermes plc is a global biopharmaceutical company primarily focused on developing innovative medicines for central nervous system (CNS) disorders. The company's mission is to research, develop, and commercialize innovative medicines that address unmet medical needs in people living with serious CNS diseases, aiming to improve patient outcomes and public health. Headquartered in Dublin, Ireland, Alkermes maintains a significant operational presence, including an R&D center, in Waltham, Massachusetts, USA, and manufacturing facilities in Wilmington, Ohio.

Alkermes operates through segments dedicated to proprietary products and partnered products. Its proprietary commercial portfolio includes Vivitrol® for alcohol and opioid dependence, Aristada® and Lybalvi® for schizophrenia, Lybalvi® for bipolar I disorder, and Lumryz® for narcolepsy. The company also generates revenue from royalties and manufacturing services for licensed products such as Risperdal Consta® and Invega Sustenna®. Alkermes leverages its scientific expertise and proprietary technologies, including injectable extended-release microsphere technology, to develop these therapies.

In a strategic move to sharpen its focus on neuroscience, Alkermes completed the separation of its oncology business into a new company, Mural Oncology, in November 2023. Further expanding its presence in sleep medicine, Alkermes completed the acquisition of Avadel Pharmaceuticals plc in February 2026, adding the FDA-approved narcolepsy treatment Lumryz® to its commercial portfolio. Richard Pops, who has served as Chairman and CEO since 1991, is slated to retire as CEO in August 2026, with current Chief Operating Officer Blair Jackson designated as his successor. The company's pipeline includes alixorexton, an investigational orexin 2 receptor agonist for narcolepsy, which received Breakthrough Therapy designation from the U.S. FDA for narcolepsy type 1 in January 2026 and is currently in Phase 3 studies. Alkermes is positioned as a significant player in the biopharmaceutical industry, particularly within the CNS and sleep medicine sectors, with a market capitalization of approximately $5.5 to $5.6 billion.